§ Mr. Alfred Morris
To ask the Secretary of State for Health if his Department has now completed its assessment of the likely need for erythropoietin and its expenditure implications, on the basis of information supplied by health authorities; if he has now determined the best way forward as referred to in theOfficial Report, column 316–17, of 23 October; and if he will make a statement.
§ Mrs. Virginia Bottomley
Erythropoietin has still not received a product licence. Information from health authorities has revealed significant variations in assumptions about the usage of the product after licensing. Discussions are taking place with the medical profession on the clinical indications for the prescription of the product.